NASDAQ · VTRSHealthcarePharmaceuticals

Viatris financials

$18.12−0.82%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Q4 '24
Dec 31
Q3 '24
Sep 30
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$3.76B$3.52B$3.70B$3.76B$3.58B$3.25B$3.53B$3.75B$3.80B$3.66B$3.84B$3.94B
Gross profit$1.46B$1.16B$1.15B$1.37B$1.33B$1.16B$1.22B$1.46B$1.45B$1.50B$1.60B$1.69B
Gross margin38.8%32.9%31.0%36.5%37.2%35.7%34.4%38.9%38.1%41.1%41.6%42.9%
Operating income$6.3M-$79.7M-$192.7M$178.8M$233.0M-$2.88B-$179.8M$225.9M-$239.9M$203.9M-$454.5M$451.7M
Net income-$118.8M$176.4M-$340.1M-$128.2M-$4.6M-$3.04B-$516.5M$94.8M-$326.4M$113.9M-$765.6M$331.6M
Net margin−3.2%5.0%−9.2%−3.4%−0.1%−93.5%−14.6%2.5%−8.6%3.1%−20.0%8.4%
Diluted EPS$-0.10$0.15$-0.29$-0.11$0.00$-2.55$-0.44$0.08$-0.27$0.09$-0.63$0.27
EBITDA$751.8M$649.9M$571.0M$923.0M$863.7M$645.8M$678.0M$927.1M$998.4M$971.7M-$306.4M$1.10B
Operating cash flow$381.8M$388.3M$815.8M$744.9M$219.7M$535.5M$482.7M$826.5M$379.1M$614.6M$568.5M$835.2M
Free cash flow$329.0M$348.4M$619.3M$658.1M$166.8M$492.9M$342.3M$749.5M$320.3M$564.8M$302.6M$739.3M
Diluted shares1,163.3M1,175.3M1,156.5M1,164.6M1,173.0M1,192.4M1,172.2M1,200.4M1,191.1M1,209.5M1,210.9M1,207.6M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$886.5M$1.80B$1.32B$975.3M$566.4M$755.0M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$13.35B$14.34B$14.41B$14.44B$14.47B$14.19B
Total assets$35.04B$36.83B$37.19B$37.92B$38.41B$38.47B
Total liabilities$20.78B$22.18B$22.48B$22.70B$22.84B$22.82B
Shareholders' equity$14.26B$14.66B$14.71B$15.22B$15.57B$15.65B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology